Targeted Protein Degradation

Pharmaron’s team has extensive experience in preparing and testing molecules for targeted protein degradation. Our comprehensive targeted protein degradation services encompass every step of the process, from synthesis and screening to pharmacology and safety evaluation, effectively advancing our clients’ molecules.

We specialize in studying various types of targeted protein degradation molecules, including:

Proteolysis-targeting chimeras
Hydrophobic tagging agents
Molecular glues, such as immunomodulatory drugs (IMiDs)

At Pharmaron, our targeted protein degradation services are tailored to meet our clients’ specific needs. We offer flexible models, including fee-for-service, full-time-equivalent (FTE), or integrated drug discovery models, to provide the best fit for our clients’ R&D goals.

Choose Pharmaron for your targeted protein degradation services and leverage our expertise to accelerate your research projects.

Capabilities

Target Identification and Validation

in vitro Biology

DMPK

in vivo Pharmacology

Safety Assessment

Integrated Drug Discovery

Our services for targeted protein degradation help drug hunters advance their molecules through every phase of drug discovery. From Target ID and Validation to API Production, we provide a complete package for IND submission.

Available Targeted Protein Degradation Services

Our team can identify potent ligands that bind to the target.
Initial molecules can be created in close collaboration with our computational drug design team, which has rich experience in ternary complex modeling.
Our extensive library of over 100 readily available protein degrader linkers and ligases facilitates the expedited synthesis of protein degrader molecules.
Our structural biology team helps unveil complex interactions at the atomic level between the protein degrader, target protein, and E3 ligase.
Biochemical and binding assays and a diverse array of cellular assays tailored to the specific molecule type and protein of interest (POI) are available for compound testing.
Target engagement, ubiquitination, target degradation, and proteasomal dependence are tested to characterize the compound.
Our in-house cell engineering team can create POI-specific cell lines that enable live monitoring of the protein degradation processes.

Advanced Screening Assays to Expedite Your Protein Degradation Project Towards IND Application Filing

Our proteomics and biomarker teams provide meaningful readouts for in vivo efficacy and PK/PD studies.
The unique challenges posed by the complex nature and mechanisms of protein degraders are addressed by experienced safety assessment and ADMET teams.
Protein degraders in biological samples, such as plasma or tissue, are quantified by our skilled bioanalysis team, equipped with highly sensitive instrumentation.
Clients can accelerate their path to IND filing by utilizing Pharmaron’s process development and GMP manufacturing capabilities.
Clients can choose package solutions for IND-enabling studies that comply with regulatory body guidance.